Exodus Point Capital Management, LP Alector, Inc. Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.19 - $6.23 $544,943 - $810,261	130,058 New	130,058 $590,000
Q2 2023 Aug 10, 2023	BUY	$5.86 - $7.93 $136,924 - $185,292	23,366 New	23,366 $140,000
Q4 2022 Feb 13, 2023	SELL	$6.88 - $9.55 $938,397 - $1.3 Million	-136,395 Reduced 73.4%	49,420 $456,000
Q3 2022 Nov 10, 2022	BUY	$8.19 - $13.2 $1.31 Million - $2.11 Million	159,928 Added 617.79%	185,815 $1.76 Million
Q2 2022 Aug 19, 2022	SELL	$7.65 - $14.24 $94,707 - $176,291	-12,380 Reduced 32.35%	25,887 $263,000
Q1 2022 May 13, 2022	SELL	$13.02 - $20.78 $99,928 - $159,486	-7,675 Reduced 16.71%	38,267 $545,000
Q4 2021 Feb 11, 2022	BUY	$19.35 - $25.54 $888,977 - $1.17 Million	45,942 New	45,942 $949,000
Q1 2021 May 17, 2021	SELL	$14.84 - $22.23 $237,172 - $355,279	-15,982 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.4 - $16.7 $16,901 - $30,026	1,798 Added 12.68%	15,982 $242,000
Q3 2020 Nov 16, 2020	SELL	$10.54 - $24.96 $19,509 - $46,200	-1,851 Reduced 11.54%	14,184 $149,000
Q2 2020 Aug 14, 2020	BUY	$21.87 - $33.11 $350,685 - $530,918	16,035 New	16,035 $392,000

168

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $153M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.